Changes in the lymph nodes during the earliest phases of rheumatoid arthritis
- Conditions
- arthritisRheumatoid arthritis10003816
- Registration Number
- NL-OMON38509
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 100
Healthy controls: negative for IgM-RF and anti-CCP antibodies
Autoantibody-positive individuals: positive for IgM-RF and/or anti-CCP antibodies + either arthralgia or a first degree relative with RA.
Early arthritis patients: arthritis < 1 year, disease-modifying antirheumatic drug (DMARD) naive + classified as RA according to the 2010 ACR/EULAR criteria for RA or as unclassified arthritis (UA).
For all individuals:
- Current/previous use of disease modifying anti-rheumatic drugs (DMARDs).
- If applicable: patients in whom anticoagulant therapy cannot be temporarily stopped before the procedure
- Systemic prednisolone use less then 28 days before enrolment
- Present or previous treatment with any cell depleting therapies, including investigational agents (e.g. CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19)
- Presence of any disease for which study subjects need chronic or intermittent immunosuppressive therapy (e.g. prednisolone for COPD).
- History of chronic viral infection
- History of autoimmune diseases
- History of malignancies
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method